What MED‑EL’s Expanded Pediatric Cochlear Implant Indications Mean for Your Practice

For decades, pediatric cochlear implant candidacy criteria lagged emerging data on early intervention and pediatric outcomes. Despite a growing body of evidence supporting earlier implantation and broader candidacy, FDA indications changed slowly creating barriers to referral, insurance coverage, and timely intervention. With MED‑EL’s newly FDA‑approved expanded pediatric indications, that gap is beginning to close.

During a recent AudiologyOnline webinar, pediatric audiologists who participated in the multicenter FDA clinical trial shared how these changes are already influencing care for children with hearing loss.

Why Expanded Indications Matter

At EHDI 2024, data showed that only about 50% of U.S. children who meet cochlear implant candidacy ultimately receive one, compared to nearly 90% in other developed countries.

As Aimee Gross, AuD, noted during the AudiologyOnline webinar: “Insurance companies often base coverage decisions on outdated FDA indications. The purpose of this research was to align FDA indications with current clinical practice and research.”

For audiologists, expanded indications provide stronger alignment between evidence-based care and the criteria families and payers rely on.

What’s New in Pediatric Candidacy?

MED-EL conducted an FDA clinical trial to evaluate outcomes in children as young as 7 months who did not meet traditional candidacy criteria.

The study reinforced what many pediatric audiologists already see clinically: earlier access and appropriate technology lead to better outcomes.

Earlier Intervention: What’s Changed for Infants

Children as young as 7 months can now be considered for bilateral cochlear implantation when they demonstrate profound hearing loss and limited auditory progress.

Victoria Gonzalez, AuD, from the University of Mississippi Medical Center emphasized how early access to sound can fundamentally change trajectories:

“The sooner the better. Even if a child isn’t ultimately a candidate yet, early referral lets us evaluate, monitor, and keep that child on our radar.”

Research shows early sensory and motor systems rely on one another to build neural connectivity, and delayed auditory access during critical periods can have lasting consequences.

Toddlers and Preschoolers: When Hearing Aids Aren’t Enough

For children ages 1–5 years old, expanded criteria recognize that children require better audibility, bandwidth, and signal-to-noise ratio than adults to develop age-appropriate spoken language.

Lisa Park, AuD, Children’s Cochlear Implant Center at the University of North Carolina highlighted how easy it is to underestimate struggles in this age group:

“These kids can look like they’re doing fine. But what gets forgotten is how much effort it takes, how tired they are, and how much they’re compensating just to keep up.”

Expanded indications give audiologists clearer justification to refer when progress plateaus even in children with residual hearing.

School‑Aged Children and Progressive Hearing Loss

The FDA approval aligns candidacy for children 6 years and older with expanded adult indications. This is particularly impactful for children with progressive or steeply sloping hearing loss, who may appear conversationally competent but struggle significantly in noise, academics, and social settings.

Dr. Park emphasized a shift in mindset:

“We’re not looking for kids to be ‘okay.’ We want them to meet their full potential.”

Want to learn more?

Hear more from the audiologists who participated in the FDA clinical trial and explore the data and real‑world implications of MED‑EL’s expanded pediatric indications in the latest AudiologyOnline webinar.